Antibody binding specifically to MUC1 and use thereof
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
1. An anti-MUC1 antibody or an antigen-binding fragment thereof recognizing a polypeptide comprising at least five consecutive amino acids in a C-terminal extracellular domain of MUC1, comprising:
a heavy-chain CDR1 of SEQ ID NO: 1; heavy-chain CDR2 of SEQ ID NO: 2; and heavy-chain CDR3 of SEQ ID NO: 3; and
a light-chain CDR1 of SEQ ID NO: 4; light-chain CDR2 of SEQ ID NO: 5; and light-chain CDR3 of SEQ ID NO: 6.
2. The anti-MUC1 antibody or the antigen-binding fragment thereof according to claim 1 , comprising:
a heavy-chain variable region of SEQ ID NO: 22 or 24; and
a light-chain variable region of SEQ ID NO: 23 or 25.
3. A bispecific antibody comprising the anti-MUC1 antibody or an antigen-binding fragment thereof according to claim 1 .
4. The bispecific antibody according to claim 3 , wherein the bispecific antibody comprises an anti-MUC1 antibody or an antigen-binding fragment thereof, and an antibody having an ability to bind to a cancer-associated antigen or an immune checkpoint protein antigen, or an immune-effector cell-specific target molecule.
5. A pharmaceutical composition for treating cancer comprising (i) the anti-MUC1 antibody or the antigen-binding fragment thereof according to claim 1 , or (ii) a bispecific antibody comprising the anti-MUC1 antibody or the antigen-binding fragment thereof.
6. A composition for diagnosing cancer comprising the anti-MUC1 antibody or the antigen-binding fragment thereof according to claim 1 .